Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
1,94 USD | -1,02% | -2,51% | -2,02% |
14/03 | PROQR THERAPEUTICS N.V. : Chardan Research mantiene la raccomandazione Buy | ZM |
13/03 | ProQR Therapeutics N.V. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023 | CI |
Attività
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
RNA Based Therapeutics
100,0
%
| 4 | 100,0 % | 7 | 100,0 % | +65,99% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 4 | 100,0 % | 7 | 100,0 % | +65,99% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Daniel de Boer
CEO | Chief Executive Officer | 41 | 21/02/12 |
Founder | 60 | 21/02/12 | |
Jurriaan Dekkers
DFI | Director of Finance/CFO | - | 01/10/22 |
Sheila Sponselee
COO | Chief Operating Officer | - | 01/04/20 |
Sarah Kiely
IRC | Investor Relations Contact | - | 01/10/19 |
Andrew Morris
PRN | Corporate Officer/Principal | - | 01/01/19 |
René Beukema
LAW | General Counsel | 60 | 01/09/13 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Domenico Valerio
FOU | Founder | 67 | 21/02/12 |
Founder | 60 | 21/02/12 | |
Alison Lawton
BRD | Director/Board Member | 62 | 17/09/14 |
Bart Filius
BRD | Director/Board Member | 53 | 21/05/19 |
James Shannon
BRD | Director/Board Member | 67 | 21/06/16 |
Theresa Heggie
COO | Chief Operating Officer | 63 | 01/07/19 |
Begoña Carreño
BRD | Director/Board Member | 52 | 01/01/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 84 248 384 | 66 003 992 ( 78,34 %) | 0 | 78,34 % |
Coordinate società
Società del gruppo
Nome | Categoria e settore |
---|---|
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. |
Pharmaceuticals: Major
|
Settore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-2,02% | 158 Mln | |
-2,31% | 103 Mrd | |
+0,56% | 95,28 Mrd | |
+1,69% | 22,15 Mrd | |
-17,37% | 21,02 Mrd | |
-9,30% | 18,15 Mrd | |
-41,01% | 16,74 Mrd | |
-14,85% | 16,05 Mrd | |
+3,21% | 13,68 Mrd | |
+33,54% | 12,17 Mrd |
- Borsa valori
- Azioni
- Azione PRQR
- Società ProQR Therapeutics N.V.